Trends in the $6 Billion Botanical Drugs Industry, 2030: An Assessment of Emerging Growth Opportunities and Strategic Developments [Yahoo! Finance]
Cardiol Therapeutics Inc. (NASDAQ: CRDL) had its "buy" rating re-affirmed by analysts at HC Wainwright. They now have a $9.00 price target on the stock.
Cardiol Therapeutics Inc. Added to PRISM Emerging Biotech Index
Cardiol Therapeutics Inc. (NASDAQ: CRDL) had its "buy" rating re-affirmed by analysts at HC Wainwright. They now have a $9.00 price target on the stock.
Are Medical Stocks Lagging Cardiol Therapeutics (CRDL) This Year? [Yahoo! Finance]